RESEARCH-USE BIOSIMILAR ANTIBODY

Enibarcimab

Monoclonal antibody · IgG1

ADMIgG1RUO

Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure.

TARGETADM
YMonoclonal antibody
CATALOGSC-BS-586
CATALOG NUMBERSC-BS-586
MOLECULAR WEIGHTApprox. 145.82 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure.

Enibarcimab is a recombinant research-use antibody directed against ADM.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Enibarcimab | StellaCyte